IL6 and rheumatoid arthritis: Previous work in rheumatoid arthritis patients receiving either biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) at the time of COVID-19 infection reported increased risk of hospitalization or death in patients using JAK inhibitors compared with either TNF inhibitors, IL-6 inhibitors or abatacept [37].